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List of abbreviations used 
OC: osteoclasts 
OB: osteoblasts 
OS: osteocytes 
RANK: receptor activator of nuclear factor  B ligand 
RANK: receptor activator of nuclear factor  B  
OPG: osteoprotegerin 
TRAFs; TNFR-associated cytoplasmic factors 
M-CSF: macrophage colony stimulating factor 
IL: interleukin 
TNF: tumor necrosis factor 
Th17: T helper 17 
gp-130: glycoprotein 130 
IFN: interferon 
TGF: transforming growth factor  
MSC: mesenchymal stem cell 
Runx2: Runt-related transcription factor 2 
Osx: osterix  
Msx2: Msh homeobox 2  
BMP: bone morphogenetic protein 
Wnt: ingless 
Hh: hedgehog 
PPAR-γ: peroxisome proliferator-activated receptor gamma 
fz: frizzled 
LRP5: low-density lipoprotein receptor-related protein 5 
GSK-3β: glycogen synthase kinase 3β 
SFRPs: secreted frizzled-related proteins  
Dkks: Dickkopfs  
Sost: sclerostin  
Krm: kremen 
PKC: protein kinase C 
JNK: c-Jun N-terminal kinase 
TAK1: TGF activated kinase 1  
TAB1:TAK1 binding protein 1 
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Dmp1: dentine matrix protein 1 
Pex: phosphate regulating neutral endopeptidase on chromosome X  
FGF: fibroblast growth factor 
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ABSTRACT 
Bone turnover is due to cyclic bone resorption followed by bone apposition; these 
processes are due to the coordinated actions of osteoclasts (OCs) and osteoblasts (OBs). 
The actions of these two cellular types are orchestrated by osteocytes (OS) that 
differentiate from osteoblasts and are the most abundant cells in bone. OCs are formed by 
the attraction of myelomonocytic precursors to the resorption site; the fusion of these cells 
generates a multinucleated cell attached to the bone surface. OBs derive from a 
mesenchymal stem cell precursor shared with adipocytes. OS are thought to be the cells 
primarily responsible for mechanosensing in bone.Numerous cytokines are thought to be 
responsible for the regulation of bone turnover; most of them have pleiotropic actions and 
are involved in the regulation of systems other than skeleton. OC formation and function 
are mainly regulated by the essential factor RANKL, whereas other cytokines increased 
during inflammation up-regulate OCs and are involved in inflammation-induced bone loss. 
OB formation and activity are believed to be mainly regulated by the Wnt and BMP 
signalling pathways. 
This review will focus on the main cytokines involved in the regulation of 
osteoclastogenesis, osteoblastogenesis and coupling of osteoclasts and osteoblasts under 
physiological and pathological conditions. 
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INTRODUCTION 
Bone is a dynamic tissue that is constantly formed and resorbed in response to changes in 
mechanical loading, altered serum calcium and pH levels. These changes are mediated by 
paracrine and endocrine factors. Bone turnover is due to continuous and cyclic bone 
resorption followed by apposition; these processes are due to the coordinated actions of 
osteoclasts (OC, which destroy bone) and osteoblasts (OB, which form bone). The actions 
of these two cellular types may be orchestrated to some extent by osteocytes (OS).  In 
physiological conditions, OB and OC activity is coupled, so that the amount of resorption is 
equal to the amount of formation. However, in pathological conditions or during 
senescence, resorption is higher than formation, leading to bone loss. OC and OB 
formation, as well as the coupling between these two cell types, are mediated mainly 
through cytokines.  
 
The aim of this review is to describe the complex cytokine network involved in the 
regulation of bone cells function, and to illustrate the close relationship between the 
skeleton and other systems, such as the immune system (D'Amelio and Isaia 2009), 
cardiovascular system (D'Amelio et al. 2009) and adipose tissue (Isaia et al. 2005).  
 
 
OSTEOCLASTS 
OCs are formed by the attraction of myelomonocytic precursors to the resorption site, 
followed by their fusion, and attachment of the subsequent multinucleated cell to the bone 
surface (Fig.1 A). 
 
RANKL/RANK/OPG system 
A central role in OC biology is played by the receptor activator of NF-kB ligand (RANKL), 
that is essential for osteoclastogenesis and bone resorption (Leibbrandt and Penninger 
2008). Mice and humans deficient in the RANKL gene completely lack OC and exhibit 
variable forms of osteopetrosis. RANKL has also been implicated in regulation of immune 
response and in arterial wall calcification (D'Amelio and Isaia 2009, D'Amelioet al. 2009). 
The functional receptor for RANKL, RANK is encoded by a tumour necrosis factor receptor 
(TNFR) superfamily gene (TNFGS11A) and is expressed on OC precursors. Mice lacking 
TNFGS11A have a profound defect in bone resorption and in the development of 
cartilaginous growth plates. One of the key steps upon activation of the RANK pathway is 
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the binding of TNFR-associated cytoplasmic factors (TRAFs) to specific domains within 
the cytoplasmic domain of RANK. The TRAF family proteins are cytoplasmic adapter 
proteins involved in the mediation of several cytokine-signalling pathways. Different 
members of the family activate different transcriptional pathways: TRAF2, 5 and 6 are 
involved in the activation of NF-kB through IkB kinase (IKK) activation and AP-1 through 
activation of mitogen-activated protein kinases (MAPKs), including Jun-N-terminal kinase 
(JNK), p38 and extracellular signal-regulated kinase (ERK). Moreover, TRAF6 functions as 
an ubiquitin ligase, which catalyzes the formation of a polyUb chain. This leads to the 
activation of IKK and JNK through a proteasome-independent mechanism (Xu et al. 2009) 
(Fig.1 B-C).  
RANKL/RANK signalling promotes the differentiation of OC precursors into mature 
multinucleated OCs, stimulates their capacity to resorb bone and decreases OC apoptosis. 
RANKL is present as both a transmembrane molecule and a secreted form, its interaction 
with RANK is opposed by osteoprotegerin (OPG), a neutralizing soluble decoy receptor, 
produced by marrow stromal cells and osteoblasts (Grundt et al. 2009). The unbalance 
between RANKL and OPG has been indicated as the pivotal mechanism responsible for 
bone loss in case of estrogen deficiency (D'Amelio et al. 2008), inflammation (Leibbrandt 
and Penninger 2008) and cancer (Fili et al. 2009) induced bone loss. 
 
M-CSF 
M-CSF induces the proliferation of OC precursors, their differentiation and increases the 
survival of mature OCs; OC formation occurs when monocytes are co-stimulated by the 
essential osteoclastogenic factors RANKL and M-CSF. In addition to RANKL, TNF- and 
IL-1 directly regulate NF-kB signalling in OC. As shown in Figure 1 B-C, RANKL activates 
both classical and alternative pathways of NF-kB; whereas TNF- and IL-1 activate the 
classical pathways.  
 
TNF- 
TNF- enhances OC formation by up-regulating stromal cells production of RANKL and M-
CSF, and by augmenting the responsiveness of OCs precursors to RANKL. TNF directly 
induces marrow precursor differentiation into OCs, although according to some studies it is 
not osteoclastogenetic in cells not previously primed by RANKL. The ability of TNF to 
increase the osteoclastogenic activity of RANKL is due to synergistic interactions at the 
level of NFkB and AP-1 signaling (Fig.1 B). In addition, TNF and RANKL synergistically up 
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regulates RANK expression. In vivo blockade of TNF in postmenopausal osteoporosis 
reduces bone resorption (Charatcharoenwitthaya et al. 2007); this suggests that TNF- 
increase could be one of the mechanisms responsible for postmenopausal bone loss. TNF 
is mainly produced by activated T cells and it is also involved in inflammation and cancer 
induced bone loss both systemically and locally.  
 
IL-1 
IL-1 plays an important role in bone loss induced by estrogen deficiency; its level 
increases after menopause, and is reversed by estrogen replacement.  Bone loss does not 
occur after ovariectomy in mice deficient in receptors for IL-1, and treatment with IL-1 
receptor antagonist decreases OC formation and activity.  A recent study demonstrates 
that the blockade of IL-1 reduces bone resorption in postmenopausal osteoporosis 
(Charatcharoenwitthayaet al. 2007). IL-1 acts by increasing RANKL expression by bone 
marrow stromal cells and directly targets OC precursors, promoting OC differentiation in 
the presence of permissive levels of RANKL (Fig.1A). The effect of TNF- on 
osteoclastogenesis is upregulated by IL-1. 
 
Additional cytokines are responsible for the up-regulation of OC formation in diseases 
such as estrogen deficiency, local and systemic inflammation and bone metastasis. Some 
of these molecules have a well established role in controlling osteoclastogenesis, while 
others have not. Among these the most involved in OC formation are IL-7, IL-17, IL-23, IL-
6, TGF and IFN. Most of these molecules are also involved in the regulation of immune 
system and this may explain some of the relationship between immune and bone cells 
(D'Amelio and Isaia 2009). 
 
IL-7 
IL-7 is known for its ability to stimulate T and B cell number and the reaction to antigenic 
stimuli Recently, a role for IL-7 has also been postulated in bone remodelling (Roato et al. 
2006, D'Amelio et al. 2006). We have demonstrated that IL-7 promotes osteoclastogenesis 
by upregulating T and B cell-derived RANKL (D’Amelio et al 2006) and that the production 
of IL-7 is downregulated by estrogen.  
In humans it has been suggested that IL-7 is osteoclastogenic in psoriatic arthritis and in 
solid tumors, also in healthy volunteer the expression of IL-7 receptor on T lymphocytes 
correlates with their ability to induce osteoclastogenesis from human monocytes. 
 9 
 
IL-17 and IL-23  
IL-17 family members are mainly expressed by a type of human T helper cell (Th17) (Yao 
et al. 1995). It is now believed that this cytokine plays a crucial role in inflammation and the 
development of autoimmune diseases such as rheumatoid arthritis,; however, its 
mechanism of action in the development of bone erosions, especially in relation to other 
known key cytokines such as IL-1, TNF- and RANKL remains unclear.  Recently, IL-17 
has been suggested to be involved in the upregulation of OC formation in inflammation by 
increasing the release of RANKL, which may synergise with IL-1 and TNF (Lubberts et al. 
2005).  
 
One of the stimuli to IL-17 production is IL-23 produced by activated dendritic cells and 
macrophages. IL-23 drives the T helper 1 response, and is a implicated in autoimmune 
diseases; hence; it has been suggested that the IL-23/IL-17 axis is critical for controlling 
inflammatory bone loss. However, in contrast to IL-17-deficient mice, IL-23 knockout mice 
were completely protected from bone and joint destruction in the collagen-induced arthritis 
model, indicating that the IL-23-induced bone loss may not be entirely mediated by IL-17, 
and raising the question whether IL-23 can directly stimulate OCs. Recent work supports 
this hypothesis suggesting that IL-23 promotes OC formation (Yago et al. 2007). Other 
recent in vivo studies suggest that IL-23 inhibits OC formation via T cells (Quinn et al. 
2008). In physiological conditions (unlike inflammatory conditions), IL-23 favours higher 
bone mass in long bones by limiting resorption of immature bone forming below the growth 
plate (Quinnet al. 2008). These contrasting data suggest different roles of this cytokine in 
the control of physiological or inflammatory bone turnover. 
 
IL6 
Activation of the signalling pathway mediated by glycoprotein (gp)-130 by IL-6 and its 
soluble receptor has been regarded as a pivotal mechanism for the regulation of 
osteoclastogenesis (Roodman 1992). Nevertheless, in IL-6 knockout mice (IL6KO), as well 
as in gp-130 deficient mice no decrease in OC formation and function was found. These 
data may suggest that IL-6 is not essential for bone resorption. However, IL6KO mice were 
protected against ovariectomy induced bone loss, and this finding, together with the 
observation of increased level of IL-6 after menopause in women, may suggest a peculiar 
role for IL-6 in bone loss due to estrogen deprivation. IL-6 was also shown to be involved 
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in other diseases associated with accelerated bone turnover such as Paget’s disease of 
bone, multiple myeloma, rheumatoid arthritis and renal osteodystrophy. 
 
IFN 
The effect of IFN on OC formation and activity is controversial. IFN behaves like an anti-
osteoclastegenic cytokine in vitro (Takayanagi et al. 2000), in vivo in nude mice (Sato et al. 
1992) and in a knock out models in which the onset of collagen induced arthritis is more 
rapid, as compared with wild type controls. These data are not confirmed by studies in 
humans and in experimental models of diseases that indicate an increased level of IFN 
during estrogen deficiency. 
In humans IFN is positively correlated with bone erosions in leprosy and rheumatoid 
arthritis. Data from randomized controlled trials have shown that IFN does not prevent 
bone loss in rheumatoid arthritis. The use of IFN in humans has been suggested to 
employ IFN for the treatment of osteopetrosis, in which condition IFN is able to restore 
bone resorption. 
Taken together, the data in humans suggest that, in some conditions, IFN stimulates 
bone resorption. These discrepancies could be explained by the fact that IFN directly 
blocks OC formation targeting maturing OC and induces antigen presentation and thus T 
cell activation in vivo. Therefore, when IFN levels are increased in vivo, activated T cells 
secrete pro-osteoclastogenic factors and this activity offsets its anti-osteoclastogenic 
effect. 
 
TGF 
TGF plays a complex role in osteoclastogenesis. It has wide ranging effects and it has 
been suggested that it may play a pivotal role in the growing skeleton contributing the 
coupling between OB and OC (Massague 1990). Three isoforms of TGF have been 
described (TGF1–3), which all interact with the same receptor complex. TGF1 is mainly 
expressed in lymphoid organs and in serum. Conversely, TGF2 and TGF3 are 
predominantly expressed in mesenchymal tissues and bone. TGF is produced by many 
cell types, including bone marrow cells, OBs and stromal cells and is secreted in a latent 
form that must be activated to mediate its effects.  Although several mechanisms of 
activation in vivo have been proposed, the precise mechanism of this process is not 
known.  Both in vitro and in vivo studies have shown that TGF1–3 have complex effects 
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on bone. They stimulate or repress proliferation or formation of OBs and Ocs, depending 
on cell types and culture conditions used. Mice with OB-specific over-expression of TGF2 
develop high turnover osteoporosis. 
TGF has also been implicated in the pathogenesis of ovariectomy-induced bone loss 
because local injection of TGF1 and TGF2 prevent bone loss at the site of the injection 
in ovariectomy rats.  Furthermore, estrogen is known to upregulate the expression of 
TGF in murine OBs, bone extracts and bone marrow cells and long-term in vivo estrogen 
treatment has been shown to increase serum TGF1 and TGF2 levels in humans. Latent 
TGF is abundantly present in the bone matrix and is released and activated during bone 
resorption, and it feeds back to modulate OB and OC activity. In particular TGF is 
believed to induce OCs apoptosis that follows bone resorption in vivo. 
 
Figure 2 summarizes the action of the above mentioned cytokines on OCs. 
 
OSTEOBLASTS 
Osteoblasts are the cells responsible for the production of bone matrix components such 
as type I collagen. OBs and adipocytes differentiate from a common precursor, the 
pluripotent mesenchymal stem cell (MSC) found in bone marrow and adipose tissue. 
Numerous transcription factors and multiple extracellular and intracellular signals 
regulating adipogenesis and osteoblastogenesis have been identified and analyzed in the 
recent years. Over the last two decades, many factors have been identified that regulate 
differentiation. Runt-related transcription factor 2 (Runx2), Osterix (Osx), Msh homeobox 2 
(Msx2), bone morphogenetic proteins (BMPs), Wnt and Hedgehog (Hh) have been shown 
to be critical in osteoblastogenesis ((Marie 2008)) (Fig.3). 
Differentiation factors controlling osteoblastogenesis inhibit adipogenesis, and vice 
versa. In MSC, the Wnt signaling pathways induce osteoblastogenesis, and stimulate OB 
proliferation and maturation. PPAR-γ a member of the nuclear hormone receptor 
superfamily, induces MSCs to differentiate into adipocytes (Fig.3). The actions of Wnt and 
PPAR-γ in osteoblastogenesis and adipogenesis have been extensively studied; however, 
their molecular interactions and the effects of this interaction have remained unclear. 
 
Wnts 
Wnts are a family of secreted lipid-modified proteins that bind to a receptor complex 
comprising frizzled (fz) and the low-density lipoprotein receptor-related proteins 5 or 6 
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(LRP5 or LRP6). Activation of this receptor leads to inactivation of glycogen synthase 
kinase 3β (GSK-3β), which prevents the proteosomal degradation of the transcriptional co-
activator β-catenin and, thereby, promotes its accumulation in the cytoplasm. β-catenin 
translocates into the nucleus and regulates the expression of Wnt target genes (Fig.4). 
Several molecules serve as antagonists of Wnt signaling: secreted frizzled-related proteins 
(SFRPs) act as soluble decoy fz receptors by preventing binding of Wnt to fz.  Dickkopfs 
(Dkks) and sclerostin (Sost) bind to and inactivate signaling from LRP5/LRP6 through 
Kremen (Krm) (Fig.4) (Macsai et al. 2008). Besides this so-called canonical pathway, Wnts 
can signal via the protein kinase C (PKC), Rho- or c-Jun N-terminal kinase (JNK) The role 
of this pathway in bone biology is still unclear.  Wnt canonical signalling is a critical 
determinant of bone mass, indeed, loss or gain of function mutations in LRP5 leads to 
osteoporosis-pseudoglioma syndrome or the hereditary high bone mass trait, respectively.  
 
BMPs 
The bone morphogenetic proteins (BMPs) are cytokines belonging to the TGF family. 
More than 20 BMPs have been identified to date and these are divided into classes based 
on their sequences and functions. Some BMPs (-2, -3, -4,-6, -7, -8 and -8b) are produced 
by preosteoblasts, while others are secreted by non-parenchymal cells of the liver (BMP-9) 
or by human endochondral and intramembranous bone.  BMP-2, -6, -7 and -9 regulate the 
proliferation, differentiation and apoptosis of bone cells. 
BMPs act on the cells involved in the bone ossification via two pathways: the canonical 
Smad pathway and a pathway involving the mitogen activated protein kinase (MAPK),  
(Senta et al. 2009)  (Fig. 5).  The Smad pathway is activated with the binding of BMPs to 
their heterotetrameric receptors. Smads form a complex that translocates into the nucleus 
and binds to a specific DNA sequence and to proteins involved in target gene expression, 
and activates OB-specific genes. The Smad pathway is regulated by the breakdown of 
Smad by the ubiquitination of the protein via the Smad-ubiquitination regulatory factor 
(Smurf1), and the subsequent proteasome proteolytic pathway. It can also be inhibited by 
extracellular antagonists of BMPs such as noggin and chordin. Intracellular I-Smad can 
interact with the type I receptor to block R-Smad phosphorylation. Smad 6 also competes 
with Smad 4, which inhibits the formation of R-Smad/Smad 4 complexes. The Wnt/β-
catenin pathway is also involved in the regulation of the Smad cascade by inhibiting GSK3.  
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The non canonical MAPK pathway involves three different cascades: an extracellular 
signal-regulated kinase (ERK), JNK and p38 MAPK. Some subgroups of BMPs, can 
activate the TGF activated kinase 1 (TAK1)/TAK1 binding protein 1 (TAB1) complex, and 
thus activate p38. Activation of this pathway also increases the degradation of Smad.  
 
TGF 
TGF can act on OB, promoting osteoprogenitor proliferation and inhibiting terminal 
differentiation, by repressing the function of Runx2 (Alliston et al. 2001). TGF also 
regulates osteoblast expression of osteoclast regulatory factors M-CSF, RANKL and OPG.  
Currently, TGF is thought to be involved mainly in coupling the actions of OC and OB and 
to play a fundamental role in the developing skeleton, whereas its role in physiological 
bone remodelling remains unclear. 
 
PPR 
PPAR-γ is a member of the nuclear receptor gene superfamily of ligand-activated 
transcription factors. Two known isoforms of PPAR-γ (1 and 2) are generated by 
alternative promoter usage and splicing, with PPAR-γ2 being predominant in adipose 
tissue.  PPAR-γ1 is expressed at lower levels in adipose tissue and in other cell types.  
The expression of both PPAR-γ1 and PPAR-γ2 is elevated during adipogenesis, and both 
isoforms can induce adipocyte differentiation and are antiosteoblastogenic. In particular, 
treatment with TNF-α or IL-1 inhibited Troglitazone (Tro)-induced transcriptional activity of 
PPAR-γ, demonstrating that cytokines may interfere with differentiation of MSC (Suzawa 
et al. 2003). Canonical Wnt signalling seems to stimulate osteoblastic differentiation 
without affecting adipo-/osteoprogenitor cells maturing into adipocytes.  However recent 
studies have shown that noncanonical Wnt signalling may directly regulate the 
transactivation function of PPAR-γ in MSCs (Takada et al. 2007)  
 
Figure 6 summarizes the regulation of transcriptional factors during osteoblastogenesis by 
multiple signals. 
 
 
OSTEOCYTES 
OSs are derived from Obs. It is not clear why some OBs are designated to become 
osteocytes, but they make connections with existing embedded cells and then are 
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engulfed in osteoid. OSs make up more than 90–95% of all bone cells in the adult 
skeleton, whereas OBs compose less than 5% and OCs less than 1%. Osteocytes are 
viable for years, even decades, whereas OBs live life-times of weeks and OCs of days. 
The unique feature of OSs is the formation of long dendritic processes that connect OSs 
within their lacunae with cells on the bone surface and into the bone marrow. Osteocytes 
send signals modulating both bone resorption and formation, but how this happens is still 
unclear. It has been suggested that dying osteocytes send signals of resorption (Verborgt 
et al. 2002, Kurata et al. 2006) and recently it has been shown that osteocytes can target 
OB trough Sost and thus inhibit bone formation (van Bezooijen et al. 2005).  OSs are 
thought to drive bone remodelling by sensing mechanical strain along their dendritic 
processes, the cilia and the cell body. 
Osteocytes influence bone remodelling through cytokines as Sost, M-CSF and RANKL. 
Sost, a Wnt antagonist, is a marker for late embedded osteocytes and its mutation in 
humans results in sclerostosis (Fig.4).  There are also three key molecules expressed in 
osteocytes that play a role in phosphate homeostasis: dentine matrix protein 1, (Dmp1), 
phosphate regulating neutral endopeptidase on chromosome X (Pex) and FGF23.   
Deletion or mutation of either Pex or Dmp1 results in hypophosphatemic rickets with 
elevation of FGF23.  FGF23 is a phosphaturic factor that prevents reabsorption of Pi by 
the kidney leading to hypophosphatemia (Fig.7). Some data suggest that Dmp1 could 
function intracellulary to regulate transcription and extracellulary to regulate mineralization 
of osteoid.  
 
Based on these observations it has proposed that the OS network can function as an 
endocrine gland to regulate phosphate homeostasis. As both Dmp1 and Pex are regulated 
by mechanical loading, it will be important to determine if skeletal loading can play a role in 
mineral and phosphate metabolism ((Bonewald 2007)). 
 
 
In summary, bone is a living tissue in which three main cells types act in response to 
multiple signals. The hormones and the cytokines involved in bone turnover have 
pleiotropic functions that may help explain the complex relationships between skeleton and 
immune and cardiovascular systems. Future studies will allow us to clarify these relations 
and to deeply understand signals involved in bone metabolism. 
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Key points 
Simplified diagram of the interactions between bone cells and other organs and systems, 
these complex pathways are mediated through multiple cytokines.  
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Key terms 
 Osteoclast: cells that resorb bone and derived from myeloid precursors. 
 Osteoblast: cells that form new bone and derived from the MSC. 
 Osteocyte: the most abundant cells in bone that orchestrate physiological bone 
remodelling; they are the mature form of osteoblasts. 
 RANKL/RANK/OPG system: the key system controlling osteoclasts, OPG is the 
decoy receptor of RANKL and inhibits osteoclastogenesis and activity. 
 Wnt signalling: together with BMPs is the key system controlling osteoblasts; it 
acts on OB commitment and activity.  
 BMPs signalling: together with Wnt is the key system controlling osteoblasts; it 
acts on OB commitment and activity. 
 Mechanotransduction: the feature that allows OS to sense mechanical load and to 
orchestrate bone remodelling and mineral homeostasis according to its variations. 
 
 
SUMMARY 
 Bone is a dynamic tissue and its turnover is due to cyclic bone resorption followed 
by apposition; these processes are due to the coordinated actions of osteoclasts 
and osteoblasts, orchestrated by osteocytes. 
 Osteoclast and osteoblast action is normally coupled in physiological conditions, 
whereas in pathological conditions their imbalance leads to bone loss. 
 Osteoclasts are formed the fusion of myelomonocytic precursors. Their recruitment, 
fusion and activation are mainly regulated by the RANK/RANKL/OPG and the NFB 
pathway. 
 Osteoclast formation is upregulated by estrogen deficiency, inflammation and 
cancer and hypoxia. 
 Osteoblasts differentiate from MSC as well as adipocytes: a central role in 
osteoblasts biology is played by the transcriptional factors that influence the MSC 
fate.  
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 The main cytokines involved in osteoblastogenesis and activity are Wnts and 
BMPs. 
 Osteocytes are the most abundant cells in bone, they are thought to regulate bone 
remodelling mainly by sensing the mechanical load. 
 Several cytokines produced by osteocytes affect bone formation and bone 
resorption. Recently, it has been proposed that these cells regulate mineral 
homeostasis by specific cytokines. 
 18 
REFERENCES. 
D'Amelio, P. and Isaia, G. 2009. Immune System and Postmenopausal Bone Loss. 
CRBMM. 7: 261-267. 
D'Amelio, P., Isaia, G. and Isaia, G.C. 2009. The osteoprotegerin/RANK/RANKL system: a 
bone key to vascular disease. JEI. 32 6-9. 
Isaia, G.C., D'Amelio, P., Di Bella, S. and Tamone, C. 2005. Is leptin the link between fat 
and bone mass? J Endocrinol Invest. 28: 61-65. 
Leibbrandt, A. and Penninger, J.M. 2008. RANK/RANKL: regulators of immune responses 
and bone physiology. Ann N Y Acad Sci. 1143: 123-150. 
Xu, J., Wu, H.F., Ang, E.S., Yip, K., Woloszyn, M., Zheng, M.H. and Tan, R.X. 2009. NF-
kappaB modulators in osteolytic bone diseases. Cytokine Growth Factor Rev. 20: 7-17. 
Grundt, A., Grafe, I.A., Liegibel, U., Sommer, U., Nawroth, P. and Kasperk, C. 2009. Direct 
effects of osteoprotegerin on human bone cell metabolism. Biochem Biophys Res 
Commun. 389: 550-555. 
D'Amelio, P., Grimaldi, A., Di Bella, S., Brianza, S.Z., Cristofaro, M.A., Tamone, C., 
Giribaldi, G., Ulliers, D., Pescarmona, G.P. and Isaia, G. 2008. Estrogen deficiency 
increases osteoclastogenesis up-regulating T cells activity: a key mechanism in 
osteoporosis. Bone. 43: 92-100. 
Fili, S., Karalaki, M. and Schaller, B. 2009. Mechanism of bone metastasis: the role of 
osteoprotegerin and of the host-tissue microenvironment-related survival factors. Cancer 
Lett. 283: 10-19. 
Charatcharoenwitthaya, N., Khosla, S., Atkinson, E.J., McCready, L.K. and Riggs, B.L. 
2007. Effect of blockade of TNF-alpha and interleukin-1 action on bone resorption in early 
postmenopausal women. J Bone Miner Res. 22: 724-729. 
Roato, I., Brunetti, G., Gorassini, E., Grano, M., Colucci, S., Bonello, L., Buffoni, L., 
Manfredi, R., Ruffini, E., Ottaviani, D., Ciuffreda, L., Mussa, A. and Ferracini, R. 2006. IL-7 
up-regulates TNF-alpha-dependent osteoclastogenesis in patients affected by solid tumor. 
PLoS One. 1: e124. 
D'Amelio, P., Grimaldi, A., Bernabei, P., Pescarmona, G.P. and Isaia, G. 2006. Immune 
system and bone metabolism: Does thymectomy influence postmenopausal bone loss in 
humans? Bone. 39: 658-665. 
Yao, Z., Painter, S.L., Fanslow, W.C., Ulrich, D., Macduff, B.M., Spriggs, M.K. and 
Armitage, R.J. 1995. Human IL-17: a novel cytokine derived from T cells. J Immunol. 155: 
5483-5486. 
 19 
Lubberts, E., Koenders, M.I. and van den Berg, W.B. 2005. The role of T-cell interleukin-
17 in conducting destructive arthritis: lessons from animal models. Arthritis Res Ther. 7: 
29-37. 
Yago, T., Nanke, Y., Kawamoto, M., Furuya, T., Kobashigawa, T., Kamatani, N. and 
Kotake, S. 2007. IL-23 induces human osteoclastogenesis via IL-17 in vitro, and anti-IL-23 
antibody attenuates collagen-induced arthritis in rats. Arthritis Res Ther. 9: R96. 
Quinn, J.M., Sims, N.A., Saleh, H., Mirosa, D., Thompson, K., Bouralexis, S., Walker, E.C., 
Martin, T.J. and Gillespie, M.T. 2008. IL-23 inhibits osteoclastogenesis indirectly through 
lymphocytes and is required for the maintenance of bone mass in mice. J Immunol. 181: 
5720-5729. 
Roodman, G.D. 1992. Interleukin-6: an osteotropic factor? J Bone Miner Res. 7: 475-478. 
Takayanagi, H., Ogasawara, K., Hida, S., Chiba, T., Murata, S., Sato, K., Takaoka, A., 
Yokochi, T., Oda, H., Tanaka, K., Nakamura, K. and Taniguchi, T. 2000. T-cell-mediated 
regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-gamma. 
Nature. 408: 600-605. 
Sato, K., Satoh, T., Shizume, K., Yamakawa, Y., Ono, Y., Demura, H., Akatsu, T., 
Takahashi, N. and Suda, T. 1992. Prolonged decrease of serum calcium concentration by 
murine gamma-interferon in hypercalcemic, human tumor (EC-GI)-bearing nude mice. 
Cancer Res. 52: 444-449. 
Massague, J. 1990. The transforming growth factor-beta family. Annu Rev Cell Biol. 6: 
597-641. 
Marie, P.J. 2008. Transcription factors controlling osteoblastogenesis. Arch Biochem 
Biophys. 473: 98-105. 
Macsai, C.E., Foster, B.K. and Xian, C.J. 2008. Roles of Wnt signalling in bone growth, 
remodelling, skeletal disorders and fracture repair. J Cell Physiol. 215: 578-587. 
Senta, H., Park, H., Bergeron, E., Drevelle, O., Fong, D., Leblanc, E., Cabana, F., Roux, 
S., Grenier, G. and Faucheux, N. 2009. Cell responses to bone morphogenetic proteins 
and peptides derived from them: biomedical applications and limitations. Cytokine Growth 
Factor Rev. 20: 213-222. 
Alliston, T., Choy, L., Ducy, P., Karsenty, G. and Derynck, R. 2001. TGF-beta-induced 
repression of CBFA1 by Smad3 decreases cbfa1 and osteocalcin expression and inhibits 
osteoblast differentiation. EMBO J. 20: 2254-2272. 
Suzawa, M., Takada, I., Yanagisawa, J., Ohtake, F., Ogawa, S., Yamauchi, T., Kadowaki, 
T., Takeuchi, Y., Shibuya, H., Gotoh, Y., Matsumoto, K. and Kato, S. 2003. Cytokines 
 20 
suppress adipogenesis and PPAR-gamma function through the TAK1/TAB1/NIK cascade. 
Nat Cell Biol. 5: 224-230. 
Takada, I., Mihara, M., Suzawa, M., Ohtake, F., Kobayashi, S., Igarashi, M., Youn, M.Y., 
Takeyama, K., Nakamura, T., Mezaki, Y., Takezawa, S., Yogiashi, Y., Kitagawa, H., 
Yamada, G., Takada, S., Minami, Y., Shibuya, H., Matsumoto, K. and Kato, S. 2007. A 
histone lysine methyltransferase activated by non-canonical Wnt signalling suppresses 
PPAR-gamma transactivation. Nat Cell Biol. 9: 1273-1285. 
Verborgt, O., Tatton, N.A., Majeska, R.J. and Schaffler, M.B. 2002. Spatial distribution of 
Bax and Bcl-2 in osteocytes after bone fatigue: complementary roles in bone remodeling 
regulation? J Bone Miner Res. 17: 907-914. 
Kurata, K., Heino, T.J., Higaki, H. and Vaananen, H.K. 2006. Bone marrow cell 
differentiation induced by mechanically damaged osteocytes in 3D gel-embedded culture. 
J Bone Miner Res. 21: 616-625. 
van Bezooijen, R.L., ten Dijke, P., Papapoulos, S.E. and Lowik, C.W. 2005. 
SOST/sclerostin, an osteocyte-derived negative regulator of bone formation. Cytokine 
Growth Factor Rev. 16: 319-327. 
Bonewald, L.F. 2007. Osteocytes as dynamic multifunctional cells. Ann N Y Acad Sci. 
1116: 281-290. 
 
 
 21 
Figure 1. Central role of NF-kB in osteoclastogenesis, regulation by RANKL, IL-1 
and TNF-. 
A. Key steps of OC formation and activity. 
B. RANKL, IL-1 and TNF- activate classical pathways of NF-kB in osteoclast-like cells.  
C. RANKL activates non classical pathways of NF-kB in osteoclast-like cells. Adapted from 
(Xuet al. 2009) 
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Figure 2. Cytokines involved in OC formation and activity. 
Schematic representation of the main cytokines involved in OC formation and activity, the 
dotted lines represent the more controversial pathways, while the continuous lines 
represent the pathways with more concordant data. 
 
Figure 3. Control of osteoblast differentiation by transcription factors. 
OB differentiation from the MSC, with the main transcription factors control involved in 
each step. Adapted from (Marie 2008). 
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Figure 4. Canonical Wnt pathway and its repressors. 
A. Activation of the canonical pathway is initiated when Wnt binds to Fz receptors and low 
LRP-5/6 co-receptors.  
B: Inactivation of canonical pathway through a variety of inhibitors mediates the 
proteasomal degradation of -catenin via its phosphorylation. Adapted from (Macsaiet al. 
2008). 
 
Figure 5. BMPs pathways. 
Classical BMP signalling pathwaysthrough Smad and MAPK, adapted from (Sentaet al. 
2009). 
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Figure 6. Regulation of transcriptional factors during osteoblastogenesis. 
Schematic representation of the signals involved in OB differentiation. Adapted from 
(Marie 2008). 
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Figure 7. Role of OSs in mineral metabolism.  
Interactions between Dmp1, Phex, and FGF23, adapted from (Bonewald 2007). 
 
